Dr. Daniel J. Wallace, MD

Dr. Wallace practices at Cedars-Sinai Medical Center in West Hollywood, California.

Dr. Wallace's NPI, 1982608717, was assigned on June 9, 2005. Dr. Wallace graduated from Keck School of Medicine of USC in 1974. Dr. Wallace's California license number on file is G30533.

Dr. Wallace's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, West Hollywood, CA 90048 in Los Angeles County. The practice phone is (323) 866-8600.

Dr. Wallace's primary practice is Cedars-Sinai Medical Center in West Hollywood, California. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Wallace to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wallace practices, 2 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Wallace's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Wallace is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Wallace's licenses on file in 2 states: California and Florida.

Dmand AI lists arteritis, arthritis, fibromyalgia and chronic pain, gout, joint pain, lupus, muscle pain, fibromyalgia, and limb pain and osteoporosis among the conditions Dr. Wallace treats.

CMS data shows 856 Medicare services from Dr. Wallace across 3 procedure codes in 2024, for 62 Medicare patients. Medicare paid $17,010 for them.

CMS counts 62 Medicare patients who saw Dr. Wallace in 2024. The largest group is 65 to 74, with 26 patients. 75% of them have arthritis, and 75% have high cholesterol. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wallace's median patient age at 60, with 82% women.

In 2024, Dr. Wallace wrote 1,615 Medicare Part D claims for 244 patients. 84% of them were for generic drugs. CMS names the drug for 1,261 of them, across 36 drugs with 11 or more claims each, at $915,242 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Wallace for performance year 2024, reported as part of a group.

Dmand AI links 246 papers to Dr. Wallace, published from 2007 to 2025. 2019 was the busiest year, with 16. The most frequent topics are Lupus Erythematosus, Systemic, Double-Blind Method and Immunosuppressive Agents. Dr. Wallace has published most often in Ann Rheum Dis. Dr. Wallace's most frequent co-authors are Kenneth Carekin Kalunian, MD, Anca D. Askanase, MD and Diane Leigh Kamen, MD.

Dmand AI links Dr. Wallace to 4 clinical trials, 3 of them phase 2 studies. Conditions studied include Lupus Erythematosus, Systemic, Connective Tissue Diseases and Arthritis, Rheumatoid.

CMS Open Payments shows 179 general payments to Dr. Wallace from 19 drug and device companies from 2024 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. AstraZeneca Pharmaceuticals LP paid the most, $49,740.

Dmand AI lists 6 awards for Dr. Wallace, most recently America's Top Doctors in 2014.

Dr. Wallace graduated from Keck School of Medicine of USC in 1974. Dr. Wallace is a member of ACR.

Dr. Wallace is in network with 7 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.